

# LEQVIO® Clinical Documentation Referral Checklist



This checklist is meant to capture the most common information typically needed by a treatment center. Use this checklist to help complete the LEQVIO Referral/Order Form and to ensure necessary clinical information in support of the referral is attached. **NOTE: You should check with the treatment center directly to confirm the process for referral and information required.**

Patient Name: \_\_\_\_\_ Date of Service: \_\_\_\_\_

## Patient has a primary diagnosis of:

☐ Hypercholesterolemia ☐ Heterozygous familial hypercholesterolemia (HeFH) ☐ Other: \_\_\_\_\_

## If patient has a history of clinical atherosclerotic cardiovascular disease (ASCVD)—select all that apply

- ☐ Angina, stable or unstable
- ☐ Coronary syndrome, acute
- ☐ Myocardial infarction, history of
- ☐ Revascularization, coronary or other arterial (coronary artery bypass grafting, percutaneous transluminal coronary angioplasty, etc)
- ☐ Peripheral arterial disease
- ☐ Positive findings in computed tomography angio or cath
- ☐ Stroke
- ☐ Transient ischemic attack
- ☐ Other: \_\_\_\_\_

OR

## If patient has an increased risk of ASCVD—select all that apply

- ☐ Age ≥65 years
- ☐ History of prior coronary artery bypass surgery or PCI outside of the major ASCVD event(s)
- ☐ Diabetes mellitus
- ☐ Hypertension
- ☐ Chronic kidney disease (eGFR 15-59 mL/min/1.73 m<sup>2</sup>)
- ☐ Current smoking
- ☐ Persistently elevated LDL-C (≥100 mg/dL [≥2.6 mmol/L])
- ☐ History of congestive heart failure
- ☐ Other: \_\_\_\_\_

AND/OR

## If patient has a history of HeFH—select all that apply

- ☐ Dutch Lipid/WHO Score >8
- ☐ Pretreatment LDL-C ≥190 mg/dL
- ☐ First or second degree relative with pretreatment LDL-C ≥190 mg/dL
- ☐ Simon Broome diagnostic criteria met
- ☐ Other: \_\_\_\_\_

☐ Relevant patient history regarding diet and exercise: \_\_\_\_\_

☐ Other relevant patient history: \_\_\_\_\_

☐ Relevant ICD-10-CM diagnosis code(s) \_\_\_\_\_

**Lab values** ☐ Relevant tests and recent lab values including LDL-C levels

## Current and previous lipid-lowering therapy—select all that apply

- ☐ Atorvastatin (LIPITOR®) ☐ 10 ☐ 20 ☐ 40 ☐ 80 ----- Dates/length of use: \_\_\_\_\_
- ☐ Pravastatin (PRAVACHOL®) ☐ 10 ☐ 20 ☐ 40 ☐ 80 ----- Dates/length of use: \_\_\_\_\_
- ☐ Simvastatin (ZOCOR®) ☐ 5 ☐ 10 ☐ 20 ☐ 40 ☐ 80 ----- Dates/length of use: \_\_\_\_\_
- ☐ Rosuvastatin (CRESTOR®) ☐ 5 ☐ 10 ☐ 20 ☐ 40 ----- Dates/length of use: \_\_\_\_\_
- ☐ Ezetimibe (ZETIA®) ☐ 10 ----- Dates/length of use: \_\_\_\_\_
- ☐ Other: \_\_\_\_\_ Dates/length of use: \_\_\_\_\_
- ☐ Patient not at recommended target despite lipid-lowering therapy

## Medical history for statin therapy—select all that apply

- ☐ Patient experienced myalgia/myositis that resolved when removed from therapy
- ☐ Patient has undergone re-challenge with lower dose statin with symptom reappearance
- ☐ Patient has known contraindications to statins
- ☐ Patient has creatine phosphokinase elevations >10x upper normal limit
- ☐ Other: \_\_\_\_\_

## IMPORTANT SAFETY INFORMATION

LEQVIO is contraindicated in patients with a prior serious hypersensitivity reaction to inclisiran or any of the excipients in LEQVIO. Serious hypersensitivity reactions have included angioedema. Adverse reactions in clinical trials (≥3% of patients treated with LEQVIO and more frequently than placebo) were injection site reaction, arthralgia, and bronchitis.

Please click [here](#) for LEQVIO full Prescribing Information.

All other trademarks are the property of their respective owners.

Licensed from Alnylam Pharmaceuticals, Inc.

## INDICATION

LEQVIO injection is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH).